Disseminated tumor cells in bone marrow and the natural course of resected esophageal cancer

Annals of Surgery

Volumn 255, Issue 6, 2012, Pages 1105-1112

  Vashist, Yogesh K ^a   Effenberger, Katharina E ^a   Vettorazzi, Eik ^a   Riethdorf, Sabine ^a   Yekebas, Emre F ^a   Izbicki, Jakob R ^a   Pantel, Klaus ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKERATIN;

ADENOCARCINOMA; ADJUVANT CHEMOTHERAPY; ADULT; AGED; ARTICLE; BONE MARROW BIOPSY; BONE MARROW CELL; CANCER RECURRENCE; CANCER SURGERY; CANCER SURVIVAL; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ESOPHAGUS CANCER; FEMALE; HAZARD RATIO; HUMAN; IMMUNOCYTOCHEMISTRY; LOG RANK TEST; LYMPH NODE; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RECURRENCE RISK; SQUAMOUS CELL CARCINOMA; TUMOR CELL; TUMOR VOLUME;

ADENOCARCINOMA; BONE MARROW NEOPLASMS; CARCINOMA, SQUAMOUS CELL; DISEASE PROGRESSION; ESOPHAGEAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASTIC CELLS, CIRCULATING; PROGNOSIS; PROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 84861354529     PISSN: 00034932     EISSN: 15281140     Source Type: Journal    
DOI: 10.1097/SLA.0b013e3182565b0b     Document Type: Article

References (48)

1. Malthaner RA, Wong RK, Rumble RB, et al. Neoadjuvant or adjuvant therapy for resectable esophageal cancer: a systematic review and meta-analysis. BMC Med. 2004;2:35.
2. Darling G. The role of lymphadenectomy in esophageal cancer. J Surg Oncol. 2009;99:189-193.
3. Orringer MB, Marshall B, Chang AC, et al. Two thousand transhiatal esophagectomies: changing trends, lessons learned. Ann Surg. 2007;246:363-372; discussion 372-374. (Pubitemid 47312120)
4. Peyre CG, Hagen JA, DeMeester SR, et al. Predicting systemic disease in patientswith esophageal cancer after esophagectomy: amultinational study on the significance of the number of involved lymph nodes. Ann Surg. 2008;248:979-985.
5. Pantel K, Brakenhoff RH, Brandt B. Detection, clinical relevance and specific biological properties of disseminating tumour cells. Nat Rev Cancer. 2008;8:329-340. (Pubitemid 351596394)
6. Izbicki JR, Hosch SB, Pichlmeier U, et al. Prognostic value of immunohistochemically identifiable tumor cells in lymph nodes of patients with completely resected esophageal cancer. N Engl J Med. 1997;337:1188-1194. (Pubitemid 27454450)
7. Koenig AM, Prenzel KL, Bogoevski D, et al. Strong impact of micrometastatic tumor cell load in patients with esophageal carcinoma. Ann Surg Oncol. 2009;16:454-462.
8. Li SH, Wang Z, Liu XY, et al. Lymph node micrometastasis: a predictor of early tumor relapse after complete resection of histologically node-negative esophageal cancer. Surg Today. 2007;37:1047-1052. (Pubitemid 350165679)
9. Leers JM, Ayazi S, Hagen JA, et al. Survival in lymph node negative adenocarcinoma of the esophagus after R0 resection with and without neoadjuvant therapy: evidence for downstaging of N status. J Am Coll Surg. 2009;208:553-556.
10. Thorban S, Rosenberg R, Busch R, et al. Epithelial cells in bone marrow of oesophageal cancer patients: a significant prognostic factor in multivariate analysis. Br J Cancer. 2000;83:35-39. (Pubitemid 30352714)
11. Macadam R, Sarela A, Wilson J, et al. Bone marrow micrometastases predict early post-operative recurrence following surgical resection of oesophageal and gastric carcinoma. Eur J Surg Oncol. 2003;29:450-454. (Pubitemid 36748589)
12. Effenberger KE, Borgen E, Eulenburg C, et al. Multicenter study on the detection of disseminated tumor cells in primary breast cancer. Cancer Research. 2009;69:5021.
13. Fehm T, Braun S, Muller V, et al. A concept for the standardized detection of disseminated tumor cells in bone marrow from patients with primary breast cancer and its clinical implementation. Cancer. 2006;107:885-892. (Pubitemid 44291136)
14. Waseem A, Karsten U, Leigh IM, et al. Conformational changes in the rod domain of human keratin 8 following heterotypic association with keratin 18 and its implication for filament stability. Biochemistry. 2004;43:1283-1295. (Pubitemid 38176526)
15. Kaifi JT, Yekebas EF, Schurr P, et al. Tumor-cell homing to lymph nodes and bone marrow and CXCR4 expression in esophageal cancer. J Natl Cancer Inst. 2005;97:1840-1847. (Pubitemid 43033904)
16. Braun S, Pantel K, Muller P, et al. Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med. 2000;342:525-533. (Pubitemid 30117892)
17. Borgen E, Pantel K, Schlimok G, et al. A European interlaboratory testing of three well-known procedures for immunocytochemical detection of epithelial cells in bone marrow. Results from analysis of normal bone marrow. Cytometry B Clin Cytom. 2006;70:400-409. (Pubitemid 44652076)
18. Borgen E, Naume B, Nesland JM, et al. Standardization of the immunocytochemical detection of cancer cells in BM and blood: I. establishment of objective criteria for the evaluation of immunostained cells. Cytotherapy. 1999;1:377-388.
19. Greene FL. AJCC Cancer StagingManual. Chicago, IL: American Joint Committee on Cancer; 2002.
20. Bosset JF, Gignoux M, Triboulet JP, et al. Chemoradiotherapy followed by surgery comparedwith surgery alone in squamous-cell cancer of the esophagus. N Engl J Med. 1997;337:161-167. (Pubitemid 27306287)
21. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998;339:1979-1984. (Pubitemid 29024130)
22. Urba SG, Orringer MB, Turrisi A, et al. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J Clin Oncol. 2001;19:305-313. (Pubitemid 32112841)
23. Stoecklein NH, Hosch SB, Bezler M, et al. Direct genetic analysis of single disseminated cancer cells for prediction of outcome and therapy selection in esophageal cancer. Cancer Cell. 2008;13:441-453. (Pubitemid 351609446)
24. Bostick PJ, Chatterjee S, Chi DD, et al. Limitations of specific reversetranscriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients. J Clin Oncol. 1998;16:2632-2640. (Pubitemid 28363026)
25. Zippelius A, Kufer P, Honold G, et al. Limitations of reverse-transcriptase polymerase chain reaction analyses for detection of micrometastatic epithelial cancer cells in bone marrow. J Clin Oncol. 1997;15:2701-2708. (Pubitemid 27289903)
26. Chiang AC, Massague J. Molecular basis of metastasis. N Engl J Med. 2008;359:2814-2823.
27. Kim MY, Oskarsson T, Acharyya S, et al. Tumor self-seeding by circulating cancer cells. Cell. 2009;139:1315-1326.
28. O'Sullivan GC, Collins JK, Kelly J, et al. Micrometastases: marker of metastatic potential or evidence of residual disease? Gut. 1997;40:512-515. (Pubitemid 27204932)
29. Bartkowiak K, Wieczorek M, Buck F, et al. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res. 2009;8:2004-2014.
30. Gnant M, Mlineritsch B, Schippinger W, et al. Endocrine therapy plus zoledronic acid in premenopausal breast cancer. N Engl J Med. 2009;360:679-691.
31. Fizazi K, Lipton A, Mariette X, et al. Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates. J Clin Oncol. 2009;27:1564-1571.
32. Braun S, Vogl FD, Naume B, et al. A pooled analysis of bone marrow micrometastasis in breast cancer. N Engl J Med. 2005;353:793-802. (Pubitemid 41215488)
33. Meng S, Tripathy D, Frenkel EP, et al. Circulating tumor cells in patients with breast cancer dormancy. Clin Cancer Res. 2004;10:8152-8162. (Pubitemid 40053373)
34. Pantel K, Alix-Panabieres C, Riethdorf S. Cancer micrometastases. Nat Rev Clin Oncol. 2009;6:339-351.
35. Wikman H, Vessella R, Pantel K. Cancer micrometastasis and tumour dormancy. Apmis. 2008;116:754-770.
36. Altorki NK, Zhou XK, Stiles B, et al. Total number of resected lymph nodes predicts survival in esophageal cancer. Ann Surg. 2008;248:221-226.
37. Bogoevski D, Onken F, Koenig A, et al. Is it time for a new TNM classification in esophageal carcinoma? Ann Surg. 2008;247:633-641. (Pubitemid 351440614)
38. Cense HA, van Eijck CH, Tilanus HW. New insights in the lymphatic spread of oesophageal cancer and its implications for the extent of surgical resection. Best Pract Res Clin Gastroenterol. 2006;20:893-906. (Pubitemid 44391338)
39. Greenstein AJ, Litle VR, Swanson SJ, et al. Effect of the number of lymph nodes sampled on postoperative survival of lymph node-negative esophageal cancer. Cancer. 2008;112:1239-1246. (Pubitemid 351429738)
40. Gu Y, Swisher SG, Ajani JA, et al. The number of lymph nodes with metastasis predicts survival in patients with esophageal or esophagogastric junction adenocarcinoma who receive preoperative chemoradiation. Cancer. 2006;106:1017-1025.
41. Natsugoe S, Yoshinaka H, Shimada M, et al. Number of lymph node metastases determined by presurgical ultrasound and endoscopic ultrasound is related to prognosis in patients with esophageal carcinoma. Ann Surg. 2001;234:613-618. (Pubitemid 33041763)
42. PeyreCG, Hagen JA, DeMeester SR, et al.The number of lymph nodes removed predicts survival in esophageal cancer: an international study on the impact of extent of surgical resection. Ann Surg. 2008;248:549-556.
43. Roder JD, Busch R, Stein HJ, et al. Ratio of invaded to removed lymph nodes as a predictor of survival in squamous cell carcinoma of the oesophagus. Br J Surg. 1994;81:410-413. (Pubitemid 24124822)
44. Kunisaki C, Makino H, Takagawa R, et al. Surgical outcomes in esophageal cancer patients with tumor recurrence after curative esophagectomy. J Gastrointest Surg. 2008;12:802-810.
45. Mariette C, Piessen G, Triboulet JP. Therapeutic strategies in oesophageal carcinoma: role of surgery and other modalities. Lancet Oncol. 2007;8:545-553. (Pubitemid 46813024)
46. Bruzzi JF, Munden RF, Truong MT, et al. PET/CT of esophageal cancer: its role in clinical management. Radiographics. 2007;27:1635-1652.
47. Kutup A, Link BC, Schurr PG, et al. Quality control of endoscopic ultrasound in preoperative staging of esophageal cancer. Endoscopy. 2007;39:715-719. (Pubitemid 47299939)
48. Schneider PM, Metzger R, Schaefer H, et al. Response evaluation by endoscopy, rebiopsy, and endoscopic ultrasound does not accurately predict histopathologic regression after neoadjuvant chemoradiation for esophageal cancer. Ann Surg. 2008;248:902-908.